Conception and design: G. Rinnerthaler; collection and assembly of data: G. Rinnerthaler; data analysis and interpretation: all authors; manuscript writing: G. Rinnerthaler and S. P. Gampenrieder; critical revising of the manuscript: S. P. Gampenrieder, R. Greil; final approval of manuscript: all authors.
This article reviews the clinically most relevant presentations at the San Antonio Breast Cancer Symposium (SABCS) 2017 on the topics lifestyle factors, hormone receptor-positive advanced disease, liquid biopsies, and prognosis.
In a retrospective analysis of the Women’s Health Initiative Observational Study, a reduction in the body mass index (BMI) of at least 5% within 3 years significantly reduced the risk of breast cancer compared to women with a stable weight (HR 0.77; 95% CI 0.78–0.98). In the MONALEESA-7 trial investigating ribociclib or placebo in combination with endocrine therapy as first-line treatment in pre- and perimenopausal women with hormone receptor-positive, human epidermal growth factor 2 (HER2)-negative metastatic breast cancer, a significantly longer progression-free survival was shown for patients treated with ribociclib compared to the placebo group (23.8 vs. 13.0 months; HR 0.55; 95% CI 0.43–0.72; P < 0.001). In a pooled toxicity and efficacy analysis of elderly women treated with a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor in combination with an aromatase inhibitor in first-line, toxicities of higher grade were more common in elderly compared to younger patients, despite comparable efficacy. And the Clinical Treatment Score post-5 years (CTS5), accurately estimated the risk of late recurrence after 5 years of adjuvant endocrine treatment using routinely available clinical parameters.
Chlebowski R, Luo J, Anderson G, Simon M, Barrington W, Reding K, et al. Abstract GS5-07: weight change in postmenopausal women and breast cancer risk in the women’s health initiative observational study. Cancer Res. 2018;78(4 suppl):GS5-07–GS5-07. CrossRef
Tripathy D, Sohn J, Im S‑A, Colleoni M, Franke F, Bardia A, et al. Abstract GS2-05: first-line ribociclib vs placebo with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer. Cancer Res. 2018;78(4 suppl):GS2-05–GS2-05. Results from the randomized phase III MONALEESA-7 trial. CrossRef
Fasching PA, Jerusalem GHM, Pivot X, Martin M, Laurentiis MD, Blackwell KL, et al. Phase III study of ribociclib (LEE011) plus fulvestrant for the treatment of postmenopausal patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2‑negative (HER2–) advanced breast cancer (aBC). J Clin Oncol. 2016;34(15 suppl):TPS624-TPS. who have received no or only one line of prior endocrine treatment (ET): MONALEESA-3. CrossRef
Singh H, Howie L, Bloomquist E, Wedam S, Amiri-Kordestani L, Tang S, et al. Abstract GS5–06: a U.S. food and drug administration pooled analysis of outcomes of older women with hormone-receptor positive metastatic breast cancer treated with a CDK4/6 inhibitor as initial endocrine based therapy. Cancer Res. 2018;78(4 suppl):GS5-06–GS5-06. CrossRef
Finn R, Liu Y, Martin M, Rugo H, Dieras V, Im S‑A, et al. Abstract P2-09-10: comprehensive gene expression biomarker analysis of CDK 4/6 and endocrine pathways from the PALOMA-2 study. Cancer Res. 2018;78(4 suppl):P2-09-10–P2-09-10. CrossRef
Sparano J, O’Neill A, Alpaugh K, Wolff A, Northfelt D, Dang C, et al. Abstract GS6-03: circulating tumor cells (CTcs) five years after diagnosis are prognostic for late recurrence in operable stage II–III breast cancer. Cancer Res. 2018;78(4 suppl):GS6-03–GS6-03. CrossRef
Stover D, Parsons H, Ha G, Freeman S, Barry B, Guo H, et al. Abstract GS3-07: genome-wide copy number analysis of chemotherapy-resistant metastatic triple-negative breast cancer from cell-free DNA. Cancer Res. 2018;78(4 suppl):GS3-07–GS3-07. CrossRef
Sestak I, Regan M, Dodson A, Viale G, Thürlimann B, Colleoni M, et al. Abstract GS6-01: integration of clinical variables for the prediction of late distant recurrence in patients with oestrogen receptor positive breast cancer treated with 5 years of endocrine therapy. Cancer Res. 2018;78(4):GS6-01–GS6-01. CrossRef
Dowsett M, Sestak I, Regan MM, Dodson A, Viale G, Thurlimann B, et al. Integration of clinical variables for the prediction of late distant recurrence in patients with estrogen receptor-positive breast cancer treated with 5 years of endocrine therapy: CTS5. J Clin Oncol. 2018; https://doi.org/10.1200/jco.2017.76.4258. PubMedCentralCrossRefPubMed
Dubsky P, Fesl C, Singer C, Pfeiler G, Kronenwett R, Hubalek M, et al. Abstract GS6-04: the EndoPredict score predicts residual cancer burden after neoadjuvant chemotherapy and after neoendocrince therapy in HR+/HER2- breast cancer patients from ABCSG 34. Cancer Res. 2018;78(4 suppl):GS6-04–GS6-04. CrossRef
- SABCS 2017: lifestyle factors, hormone receptor-positive advanced disease, liquid biopsies, and prognosis
Simon Peter Gampenrieder
- Springer Vienna
Neu im Fachgebiet Onkologie
Mail Icon II